# Human Milk Oligosaccharides (HMOs) Post-market Study on Infants

> **NCT04055363** · NA · COMPLETED · sponsor: **Société des Produits Nestlé (SPN)** · enrollment: 207 (actual)

## Conditions studied

- Growth
- Tolerance
- Adverse Event
- Disorder of Intestine
- Disorder Lung

## Interventions

- **OTHER:** HMO-supplemented infant formula

## Key facts

- **NCT ID:** NCT04055363
- **Lead sponsor:** Société des Produits Nestlé (SPN)
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2018-11-30
- **Final completion:** 2018-12-31
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2019-08-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04055363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04055363, "Human Milk Oligosaccharides (HMOs) Post-market Study on Infants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04055363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*